Anaemia occurs when erythropoiesis, the production of red blood cells, is disturbed. Anaemia is a common complication in Chronic Kidney Disease (CKD) patients and is, typically, associated with poor concentration, loss of cognitive function and debilitating fatigue. Almost 40-50 percent of all CKD cases are caused due to diabetes. The development of anaemia in CKD is basically due to complete or relative deficiency of erythropoietin. Further, anaemia in CKD aggravates the adverse outcomes in CKD and worsens comorbid conditions.

At Roche, we are simplifying anaemia management and improving the overall quality of life of patients with our innovative products for the treatment of CKD-related anaemia.

Safety Update Information for Healthcare Professionals
I understand the following:
The information contained in this Letter is for the sole purpose of use and knowledge of Healthcare Professionals (HCPs) Only. 
If any Individual other than HCPs access the information contained in this Letter and act thereon, then Roche will not be liable for any consequences in relation thereto.
Patients and their relatives should not access the information contained in this Letter. They are advised to consult their treating physicians.